Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Enterome Bioscience and Gustave Roussy have formed a microbiome-based collaboration to develop novel Immunotherapy solutions to treat cancer.
Subscribe to our email newsletter
The partnership is based around Enterome’s metagenomic technology platform that offers an insight of the gut microbiome composition.
The composition plays an important role in identifying how effective cancer immunotherapies are and in finding personalized ways to increase immune response against tumours.
Enterome said a quantitative metagenomics plateform is based on full sequencing and mapping of total fecal bacterial gene content that allows the characterization of a personal metagenome associated with a disease phenotype.
It allows the identification of biomarkers and of bacteria of interest associated with the development of diseases.
A functional metagenomics plateform is based on the screening of genomic or metagenomics libraries on cell based assays and on specific pathways of interest that enables the discovery and the development of news drugs and targets.
Enterome CEO Pierre Bélichard said: "Still a largely unexplored field, the gut microbiome offers numerous promising avenues for research that may soon lead to a shift to a new treatment paradigm in oncology."
The gut microbiome plays an important role in the pathogenesis of inflammatory bowel diseases such as Crohn’s disease, ulcerative colitis, or celiac disease, which are chronic, relapsing and remitting set of conditions.
They characterized by an excessive inflammatory response, resulting in the destruction of the gastrointestinal tract.